share_log

Stocks of the Hour: ABx Group, Lumos Diagnostics, OD6 Metals

Stocks of the Hour: ABx Group, Lumos Diagnostics, OD6 Metals

熱門股票:abX 集團、Lumos Diagnostics、OD6 Metals
sharecafe ·  2023/07/17 22:23

ABx Group (ASX:ABX) announced that their REE Mineral Resource increased by 30% to 27 million tonnes. MD and CEO Mark Cooksey said in response, "Our northernmost discovery hole, located 5km NE of Deep Leads, could become our best prospect because it is 11 metres thick and enriched in permanent magnet rare earths, especially Dy and Tb." Shares are trading 2.5 per cent higher at 10.25 cents.

ABx集團(澳大利亞證券交易所股票代碼:ABX)宣佈,其稀土礦產資源增長了30%,達到2700萬噸。總經理兼首席執行官馬克·庫克西回應說:“我們最北端的發現洞位於Deep Leads東北5公里處,可能成爲我們最好的前景,因爲它厚11米,富含永磁稀土,尤其是Dy和Tb。”股價上漲2.5%,至10.25美分。

Lumos Diagnostics (ASX:LDX) has signed an agreement with Henry Schein Medical, S.L.U. for the FebriDx point-of-care test. In response, Doug Ward, CEO of Lumos Diagnostics, said "With our recent US clearance and the growing commercial interest in FebriDx, we are now preparing production of FebriDx to meet the anticipated growing demand for the product." Shares are trading 12.99 per cent higher at 8.7 cents.

Lumos Diagnostics(澳大利亞證券交易所股票代碼:LDX)已與S.L.U. Henry Schein Medical簽署了FebriDx即時護理測試協議。作爲回應,Lumos Diagnostics首席執行官道格·沃德表示:“隨着我們最近在美國的批准以及對FebriDx的商業興趣與日俱增,我們現在正在準備生產FebriDx,以滿足對該產品預期不斷增長的需求。”股價上漲12.99%,至8.7美分。

OD6 Metals (ASX:OD6) announced a Maiden Mineral Resource estimate for its Splinter Rock Rare Earth Project. Brett Hazelden, Managing Director, commented: "With less than 5% of our clay basin area tested and phase three drilling underway, over the next 6 to 18 months there is significant potential to grow the resource base by applying our geometallurgical exploration techniques." Shares are trading 26.67 per cent higher at 28.5 cents.

OD6 Metals(澳大利亞證券交易所股票代碼:OD6)宣佈了其Splinter Rock稀土項目的首次礦產資源估算。董事總經理Brett Hazelden評論說:“由於我們只有不到5%的粘土盆地進行了測試,第三階段的鑽探正在進行中,在接下來的6至18個月中,通過應用我們的地質金屬勘探技術來擴大資源基礎的巨大潛力。”股價上漲26.67%,至28.5美分。

1x1.png?futu_img_keep_extra_domain=1

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論